Alembic Pharmaceuticals Limited (BOM:533573)
India · Delayed Price · Currency is INR 735.10
-19.50 (-2.58%)
At close: May 29, 2026
Alembic Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 6,748 | 5,834 | 6,158 | 3,420 | 5,209 |
Depreciation & Amortization | 3,186 | 2,786 | 2,727 | 2,754 | 2,868 |
Other Amortization | - | - | - | 984.4 | 801.3 |
Loss (Gain) From Sale of Assets | 21.7 | -32.6 | -17 | 47 | -5.4 |
Asset Writedown & Restructuring Costs | 183.5 | - | - | - | - |
Loss (Gain) From Sale of Investments | 8.4 | -4 | -27.6 | -1.4 | - |
Loss (Gain) on Equity Investments | -2.4 | -8.7 | 9.8 | 309.2 | -52.8 |
Provision & Write-off of Bad Debts | 9.3 | 34.6 | 53.6 | - | 73 |
Other Operating Activities | 241.8 | 1,484 | 84.8 | 301.7 | 303.6 |
Change in Accounts Receivable | 77.3 | -3,950 | 390.5 | -2,229 | -4,696 |
Change in Inventory | -2,225 | -6,446 | -1,683 | 1,344 | -1,236 |
Change in Accounts Payable | -492.7 | 1,462 | 560.4 | -281.7 | 366.7 |
Change in Other Net Operating Assets | 72.2 | -279.1 | -224.6 | 590.5 | 1,892 |
Operating Cash Flow | 7,827 | 879.7 | 8,032 | 7,240 | 5,524 |
Operating Cash Flow Growth | 789.77% | -89.05% | 10.95% | 31.07% | -62.26% |
Capital Expenditures | -4,346 | -5,636 | -3,275 | -4,434 | -4,256 |
Sale of Property, Plant & Equipment | 21.7 | 97.7 | 115.6 | 18.7 | 13.9 |
Sale (Purchase) of Intangibles | -602.6 | - | - | - | - |
Investment in Securities | - | -211.3 | - | -70 | 476.8 |
Other Investing Activities | -133.5 | 65.7 | -47 | 9.5 | 46 |
Investing Cash Flow | -5,061 | -5,684 | -3,206 | -4,476 | -3,720 |
Short-Term Debt Issued | 230.4 | 7,651 | - | 2,059 | 4,300 |
Long-Term Debt Issued | 1,423 | - | - | - | - |
Total Debt Issued | 1,653 | 7,651 | - | 2,059 | 4,300 |
Short-Term Debt Repaid | - | - | -2,054 | - | - |
Long-Term Debt Repaid | -244.3 | -265.6 | -258.2 | -2,231 | -3,202 |
Total Debt Repaid | -244.3 | -265.6 | -2,312 | -2,231 | -3,202 |
Net Debt Issued (Repaid) | 1,409 | 7,386 | -2,312 | -172.3 | 1,098 |
Common Dividends Paid | -2,162 | -2,162 | -1,573 | -1,966 | -2,752 |
Other Financing Activities | -884.3 | -786.3 | -493.9 | -481.7 | -519.7 |
Financing Cash Flow | -1,638 | 4,437 | -4,379 | -2,620 | -2,174 |
Miscellaneous Cash Flow Adjustments | 0.1 | - | 0.1 | -0.1 | - |
Net Cash Flow | 1,129 | -367.3 | 447.3 | 143.9 | -369.7 |
Free Cash Flow | 3,481 | -4,757 | 4,757 | 2,805 | 1,267 |
Free Cash Flow Growth | - | - | 69.58% | 121.40% | -84.24% |
Free Cash Flow Margin | 4.74% | -7.13% | 7.64% | 4.96% | 2.39% |
Free Cash Flow Per Share | 17.71 | -24.20 | 24.20 | 14.27 | 6.45 |
Cash Interest Paid | 881.4 | 785.9 | 493.7 | 497 | 519.2 |
Cash Income Tax Paid | 1,037 | 714 | 198.5 | 607 | 1,234 |
Levered Free Cash Flow | 284.85 | -7,272 | 2,198 | 504.46 | -324.73 |
Unlevered Free Cash Flow | 870.04 | -6,780 | 2,549 | 818.03 | -213.91 |
Change in Working Capital | -2,568 | -9,214 | -956.5 | -575.6 | -3,673 |